Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery Platform
Recipient : Hanall Biopharma
Deal Size : $300.0 million
Deal Type : Licensing Agreement
HanAll Signs Licensing Agreement with Turn Biotechnologies for Eye and Ear Treatments
Details : The collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery Platform
Recipient : Hanall Biopharma
Deal Size : $300.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?